Drug Trial Radar · NCT02750332
Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)
Last checked: Nov 19, 2026Latest source record: Mar 15, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Nov 2015
Primary completion
Dec 2015
Study completion Jan 2016
Sponsor
- Lead sponsor
- Cycle Pharmaceuticals Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Apr 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the bioavailability of the Test Product, Nitisinone 10 mg Tablet, under fasting and fed conditions (food-effect).
Conditions
- Hereditary Tyrosinemia, Type I
Interventions
NitisinoneDrug
A single oral dose of Nitisinone 10 mg Tablet will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax)Time frame: 0 - 120 hours post-dose
- Area Under the Plasma Concentration Versus Time Curve (AUC(0-120))Time frame: 0 - 120 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa)
Bloemfontein, Free State, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.